Johnson & Johnson's ICOTYDE Shows Strong 2-Year Psoriasis Data…

Event summary

Johnson & Johnson's ICOTYDE (icotrokinra) demonstrated robust 2-year results in treating moderate-to-severe plaque psoriasis in adults and adolescents.
72% of patients achieved PASI 90 (90% skin clearance) and 70% achieved IGA 0/1 (clear or almost clear skin) at Week 112.
No new safety signals were identified, maintaining a favorable safety profile.
Data presented at Fall Clinical Dermatology Conference 2026.

The big picture

Johnson & Johnson's ICOTYDE represents a significant advancement in the treatment of plaque psoriasis, offering a targeted oral peptide that blocks the IL-23 receptor. The 2-year data reinforces its potential as a long-term solution for a chronic disease, addressing a substantial unmet need in dermatology. The results position ICOTYDE as a key player in the evolving landscape of psoriasis treatments, with broader implications for autoimmune and inflammatory disease management.

What we're watching

Market Differentiation: Whether ICOTYDE's long-term efficacy and safety data will solidify its position as a first-line systemic therapy for plaque psoriasis.
Regulatory Approvals: The pace at which ICOTYDE gains approvals for additional indications, including psoriatic arthritis, ulcerative colitis, and Crohn's disease.
Competitive Landscape: How ICOTYDE's performance will compare against existing and emerging treatments in the plaque psoriasis market.